The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis

Cardiovascular Research

Volumn 100, Issue 3, 2013, Pages 472-480

  Menini, Stefano ^a   Iacobini, Carla ^a   Ricci, Carlo ^a   Fantauzzi, Claudia Blasetti ^a   Salvi, Laura ^a   Pesce, Carlo M ^b   Relucenti, Michela ^a   Familiari, Giuseppe ^a   Taurino, Maurizio ^a   Pugliese, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Galectin 3; RAGE; Vascular calcificationm Inflammation; Wnt catenin

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; GALECTIN 3; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; BONE METABOLISM; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN TISSUE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VASCULAR SMOOTH MUSCLE;

GALECTIN-3; INFLAMMATION; RAGE; VASCULAR CALCIFICATION; WNT/Β-CATENIN;

AGED; ALKALINE PHOSPHATASE; ANIMALS; CAROTID ARTERIES; CAROTID STENOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOGENESIS; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR CALCIFICATION; WNT SIGNALING PATHWAY;

EID: 84887969430     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt206     Document Type: Article

References (38)

1. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1:297-329.
2. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15:2959-2964.
3. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation 2007; 116:2782-2785.
4. Ehara S, Kobayashi Y, Yoshiyama M., Shimada K, Shimada Y, Fukuda D et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intra-vascular ultrasound study. Circulation 2004; 110:3424-3429.
5. Kataoka Y, Wolski K, Uno K., Puri R, Tuzcu EM, Nissen SE et al. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insightsfrom serial intra-vascular ultrasound. J Am Coll Cardiol 2012; 59:1592-1597.
6. Negre-Salvayre A., Coatrieux C, Ingueneau C., Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008; 153:6-20.
7. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67:3-21.
8. Virella G, Thorpe SR, Alderson N.L., Derrick MB, Chassereau C, Rhett JM et al. Definition of the immunogenicforms of modified human LDL recognized by humanauto antibodies and by rabbit hyperimmune antibodies. J Lipid Res 2004; 45:1859-1867.
9. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196:9-21.
10. Zhu W, Sano H, Nagai R., Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001; 280:1183-1188.
11. Iacobini C, Menini S, Ricci C., Scipioni A, Sansoni V, Cordone S et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009; 29:831-836.
12. Wang Z, Jiang Y, Liu N., Ren L, Zhu Y, An Y et al. Advanced glycation end-product N1-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012; 221:387-396.
13. Hofmann Bowman M.A., Gawdzik J, Bukhari U., Husain AN, Toth PT, Kim G et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011; 31:337-344.
14. Stock M, Schäfer H, Stricker S, Gross G, Mundlos S, Otto F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 2003; 278:17360-17367.
15. Zhou Z, Immel D, Xi C.X., Bierhaus A., Feng X, Mei L et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203:1067-1080.
16. Stary HC, Chandler AB, Dinsmore R.E., Fuster V., Glagov S, Insull W Jr et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355-1374.
17. Hunt JL, Fairman R, Mitchell M.E., Carpenter JP, Golden M, Khalapyan T et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33:1214-1249.
18. Moreno PR, Purushothaman KR, Fuster V, Echeverri D., Truszczynska H, Sharma SK et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004; 110:2032-2038.
19. Vengrenyuk Y, Cardoso L, Weinbaum S. Micro-CT based analysis of a new paradigm for vulnerable plaque rupture: cellular microcalcifications in fibrous caps. Mol Cell Biomech 2008; 5:37-47.
20. Kislinger T, Fu C, Huber B., Qu W, Taguchi A, Du Yan S et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274:31740-31749.
21. Hofmann MA, Drury S, Fu C., Qu W, Taguchi A, Lu Y et al. RAGE mediatesanovel proin-flammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901.
22. Iacobini C, Menini S, Ricci C., Scipioni A, Sansoni V, Mazzitelli G et al. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J Pathol 2009; 218:360-369.
23. Byon CH, Sun Y, Chen J., Yuan K, Mao X, Heath JM et al. Runx2-upregulated receptor activator of nuclear factork Bligandincalcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011; 31: 1387-1396.
24. Iacobini C, Menini S, Oddi G., Ricci C, Amadio L, Pricci F et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004; 18:1773-1775.
25. Fadini GP, Albiero M, Menegazzo L., Boscaro E, Vigili de Kreutzenberg S, Agostini C et al. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res 2011; 108:1112-1121.
26. Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007; 148:2630-2634.
27. Shimura T, Takenaka Y, Fukumori T., Tsutsumi S, Okada K, Hogan V et al. Implication of galectin-3 in Wnt signaling. Cancer Res 2005; 65:3535-3537.
28. Li G, Xu J, Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3 K and ERK signaling. Biochem Biophys Res Commun 2012; 423:684-689.
29. Tanikawa T, Okada Y, Tanikawa R., Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46:572-580.
30. Shaalan WE, Cheng H, Gewertz B., Mc Kinsey JF, Schwartz LB, Katz D et al. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg 2004; 40:262-269.
31. Nandalur KR, Hardie AD, Raghavan P, Schipper M.J., Baskurt E., Kramer CM Composition of the stable carotid plaque: insights from a multidetector computed tomography study of plaque volume. Stroke 2007; 38:935-940.
32. Nachtigal M, Al-Assaad Z, Mayer E.P., Kim K., Monsigny M. Galectin-3 expression inhuman atherosclerotic lesions. Am J Pathol 1998; 152:1199-1208.
33. Colnot C, Sidhu SS, Poirier F, Balmain N. Cellular and subcellular distribution of galectin-3 in the epiphyseal cartilage and bone of fetal and neonatal mice. Cell Mol Biol 1999; 45:1191-1202.
34. Li Y-J, Kukita A., Teramachi J, Nagata K, Wu Z., Akamine A et al. Apossible suppressiverole of galectin-3in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats. Lab Invest 2009; 89:26-37.
35. Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-k B signaling in atherosclerotic calcification. Circ Res 2011; 108: 1482-1493.
36. Parhami F, Morrow AD, Balucan J, Leitinger N., Watson AD, Tintut Y et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17:680-687.
37. Franke S, Rüster C, Pester J, Hofmann G, Oelzner P, Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol 2011; 29: 650-660.
38. Li R, Mittelstein D, Lee J., Fang K, Majumdar R, Tintut Y et al. A dynamic model of calcific nodule destabilization in response to monocyte- and oxidized lipid-induced matrix metalloproteinases. Am J Physiol Cell Physiol 2012; 302:C658-C665.